SAN FRANCISCO (GenomeWeb) – The Mount Sinai Health system this week spun out a new company, Sema4, that will offer the same genetic tests that had been available to patients at Mt. Sinai, but will now do so nationally.

It also plans to expand the testing menu and will look to integrate machine learning and data science to move into predictive medicine, said Eric Schadt, who will serve as CEO of Sema4. Schadt will also maintain a faculty position at Mt. Sinai, as well as an active lab that will collaborate with Sema4 on building predictive models of disease.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

ScienceInsider reports that a new security policy at the US Food and Drug Administration may prevent foreign nationals from working there.

WBUR in Boston looks into Orig3n's genetic fitness assessments to find more research is needed.

Cleveland.com reports that getting a DNA profile removed from a law enforcement database can be tricky.

In PNAS this week: de novo mutations contribute to non-syndromic craniosynostosis, fungal tree of life, and more.